223 related articles for article (PubMed ID: 34469062)
21. Identification of immune infiltration and cuproptosis-related subgroups in Crohn's disease.
Yuan Y; Fu M; Li N; Ye M
Front Immunol; 2022; 13():1074271. PubMed ID: 36466876
[TBL] [Abstract][Full Text] [Related]
22. Identification and validation of key long non-coding RNAs using co-expression network analysis in Crohn's disease.
Rui Q; Lu C; Song S; Zhang L
Ann Palliat Med; 2021 Sep; 10(9):9627-9639. PubMed ID: 34628888
[TBL] [Abstract][Full Text] [Related]
23. Ustekinumab Does Not Increase Risk of Adverse Events: A Meta-Analysis of Randomized Controlled Trials.
Rolston VS; Kimmel J; Popov V; Bosworth BP; Hudesman D; Malter LB; Hong S; Chang S
Dig Dis Sci; 2021 May; 66(5):1631-1638. PubMed ID: 32445049
[TBL] [Abstract][Full Text] [Related]
24. Intravenous Ustekinumab Reinduction Is Effective in Prior Biologic Failure Crohn's Disease Patients Already on Every-4-Week Dosing.
Sedano R; Guizzetti L; McDonald C; Jairath V
Clin Gastroenterol Hepatol; 2021 Jul; 19(7):1497-1498.e1. PubMed ID: 32763479
[TBL] [Abstract][Full Text] [Related]
25. Drug Levels in the Maternal Serum, Cord Blood and Breast Milk of a Ustekinumab-Treated Patient with Crohn's Disease.
Klenske E; Osaba L; Nagore D; Rath T; Neurath MF; Atreya R
J Crohns Colitis; 2019 Feb; 13(2):267-269. PubMed ID: 30388211
[TBL] [Abstract][Full Text] [Related]
26. Association between ustekinumab trough concentrations and biochemical outcomes in patients with Crohn's disease. A real life study.
Gómez Espín R; Nicolás De Prado I; Gil Candel M; González Carrión M; Rentero Redondo L; Iniesta Navalón C
Rev Esp Enferm Dig; 2021 Feb; 113(2):110-115. PubMed ID: 33213170
[TBL] [Abstract][Full Text] [Related]
27. Constructing models for Crohn's disease diagnosis and prediction of infliximab non-response based on angiogenesis-related genes.
Zheng C; Chen X; Ke Y; Xu X; Wu C; Jiang L
Front Immunol; 2024; 15():1239496. PubMed ID: 38343536
[TBL] [Abstract][Full Text] [Related]
28. Reasons and Factors Contributing to Chinese Patients' Preference for Ustekinumab in Crohn's Disease: A Multicenter Cross-Sectional Study.
Yao L; Zhu X; Shao B; Liu R; Li Z; Wu L; Chen J; Cao Q
Front Pharmacol; 2021; 12():736149. PubMed ID: 34887751
[No Abstract] [Full Text] [Related]
29. Ustekinumab Therapeutic Drug Monitoring-Impact on Clinical Practice: A Multicenter Cross-Sectional Observational Trial.
Afif W; Sattin B; Dajnowiec D; Khanna R; Seow CH; Williamson M; Karra K; Wang Y; Gao LL; Bressler B
Dig Dis Sci; 2022 Jul; 67(7):3148-3157. PubMed ID: 34401983
[TBL] [Abstract][Full Text] [Related]
30. Anti-IL-12/23p40 antibodies for maintenance of remission in Crohn's disease.
Davies SC; Nguyen TM; Parker CE; MacDonald JK; Jairath V; Khanna R
Cochrane Database Syst Rev; 2019 Dec; 12(12):CD012804. PubMed ID: 31828765
[TBL] [Abstract][Full Text] [Related]
31. Combined Use of Three Machine Learning Modeling Methods to Develop a Ten-Gene Signature for the Diagnosis of Ventilator-Associated Pneumonia.
Cai Y; Zhang W; Zhang R; Cui X; Fang J
Med Sci Monit; 2020 Feb; 26():e919035. PubMed ID: 32031163
[TBL] [Abstract][Full Text] [Related]
32. Serum Ustekinumab Concentrations Are Associated With Remission in Crohn's Disease Defined by a Serum-Based Endoscopic Healing Index.
Walshe M; Borowski K; Battat R; Hudesman D; Wolf DC; Okada L; Jain A; Silverberg MS
Crohns Colitis 360; 2021 Jul; 3(3):otab032. PubMed ID: 36776648
[TBL] [Abstract][Full Text] [Related]
33. Preliminary experience of maintenance treatment with intravenous ustekinumab as a rescue treatment for loss of response to subcutaneous doses.
Pérez Valle I; Varela Trastoy P; Mancebo Mata A
Rev Esp Enferm Dig; 2021 Mar; 113(3):186-188. PubMed ID: 33222477
[TBL] [Abstract][Full Text] [Related]
34. Crescentic IgA nephropathy after administration of human monoclonal interleukin-12/23p40 antibody in a patient with Crohn's disease: a case report.
Kanazawa N; Wada Y; Akiyama M; Shikida Y; Sugiyama M; Abe M; Iyoda M; Honda K; Shibata T
CEN Case Rep; 2020 Aug; 9(3):204-209. PubMed ID: 32100251
[TBL] [Abstract][Full Text] [Related]
35. Identification of potential predictive biomarkers and biological pathways and the correction with immune infiltration in the activation of Crohn's disease.
Zhong WM; Qian XH; Jin ZW
Immunogenetics; 2022 Dec; 74(6):527-537. PubMed ID: 35861879
[TBL] [Abstract][Full Text] [Related]
36. Positioning Ustekinumab in Crohn's Disease: From Clinical Evidence to Clinical Practice.
Danese S; Bonovas S; Peyrin-Biroulet L
J Crohns Colitis; 2017 Oct; 11(10):1258-1266. PubMed ID: 28575273
[TBL] [Abstract][Full Text] [Related]
37. Identification of Immune Cell Landscape and Construction of a Novel Diagnostic Nomogram for Crohn's Disease.
Chen H; Chen C; Yuan X; Xu W; Yang MQ; Li Q; Shen Z; Yin L
Front Genet; 2020; 11():423. PubMed ID: 32425988
[TBL] [Abstract][Full Text] [Related]
38. Ustekinumab Exposure-outcome Analysis in Crohn's Disease Only in Part Explains Limited Endoscopic Remission Rates.
Verstockt B; Dreesen E; Noman M; Outtier A; Van den Berghe N; Aerden I; Compernolle G; Van Assche G; Gils A; Vermeire S; Ferrante M
J Crohns Colitis; 2019 Jul; 13(7):864-872. PubMed ID: 30715258
[TBL] [Abstract][Full Text] [Related]
39. Baseline Peripheral Blood Mononuclear Cell Transcriptomics Before Ustekinumab Treatment Is Linked With Crohn's Disease Clinical Response at 1 Year.
Granot M; Braun T; Efroni G; Picard O; Fudim E; Yavzori M; Haj O; Weiss B; Ben-Horin S; Kopylov U; Haberman Y
Clin Transl Gastroenterol; 2023 Dec; 14(12):e00635. PubMed ID: 37655708
[TBL] [Abstract][Full Text] [Related]
40. Identifying candidate genes for discrimination of ulcerative colitis and Crohn's disease.
Lin LJ; Zhang Y; Lin Y; Jin Y; Zheng CQ
Mol Biol Rep; 2014 Oct; 41(10):6349-55. PubMed ID: 25182475
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
